CN116869169B - Composition with function of relaxing bowels and preparation method and application thereof - Google Patents
Composition with function of relaxing bowels and preparation method and application thereof Download PDFInfo
- Publication number
- CN116869169B CN116869169B CN202311149911.6A CN202311149911A CN116869169B CN 116869169 B CN116869169 B CN 116869169B CN 202311149911 A CN202311149911 A CN 202311149911A CN 116869169 B CN116869169 B CN 116869169B
- Authority
- CN
- China
- Prior art keywords
- glucan
- beta
- alpha
- stachyose
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 230000002040 relaxant effect Effects 0.000 title claims abstract description 13
- 229920005640 poly alpha-1,3-glucan Polymers 0.000 claims abstract description 56
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims abstract description 54
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims abstract description 52
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 36
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 235000013376 functional food Nutrition 0.000 claims abstract description 14
- 230000013872 defecation Effects 0.000 claims abstract description 13
- 206010010774 Constipation Diseases 0.000 claims description 49
- 230000001965 increasing effect Effects 0.000 claims description 11
- 235000013305 food Nutrition 0.000 claims description 10
- 229930006000 Sucrose Natural products 0.000 claims description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 9
- 239000000126 substance Substances 0.000 claims description 9
- 239000005720 sucrose Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 7
- 238000005303 weighing Methods 0.000 claims description 6
- 150000004676 glycans Chemical class 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 230000002475 laxative effect Effects 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 238000000855 fermentation Methods 0.000 claims description 3
- 230000004151 fermentation Effects 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000004904 shortening Methods 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000002131 composite material Substances 0.000 claims 1
- 230000002195 synergetic effect Effects 0.000 abstract description 5
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 21
- 229920002498 Beta-glucan Polymers 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 17
- 210000003608 fece Anatomy 0.000 description 17
- 230000000694 effects Effects 0.000 description 15
- 210000001035 gastrointestinal tract Anatomy 0.000 description 15
- 230000000968 intestinal effect Effects 0.000 description 13
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 12
- 206010016100 Faeces discoloured Diseases 0.000 description 10
- 235000013406 prebiotics Nutrition 0.000 description 10
- 230000006870 function Effects 0.000 description 9
- 230000002550 fecal effect Effects 0.000 description 8
- 239000013642 negative control Substances 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000008855 peristalsis Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 235000013325 dietary fiber Nutrition 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 229920001542 oligosaccharide Polymers 0.000 description 4
- 150000002482 oligosaccharides Chemical class 0.000 description 4
- 150000004666 short chain fatty acids Chemical class 0.000 description 4
- 241000186000 Bifidobacterium Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 239000008141 laxative Substances 0.000 description 3
- 229960002983 loperamide hydrochloride Drugs 0.000 description 3
- PGYPOBZJRVSMDS-UHFFFAOYSA-N loperamide hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 PGYPOBZJRVSMDS-UHFFFAOYSA-N 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical class [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 229920001503 Glucan Polymers 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 206010042434 Sudden death Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000006047 digesta Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 208000014617 hemorrhoid Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 229940125722 laxative agent Drugs 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 229960001571 loperamide Drugs 0.000 description 2
- RDOIQAHITMMDAJ-UHFFFAOYSA-N loperamide Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)N(C)C)CCN(CC1)CCC1(O)C1=CC=C(Cl)C=C1 RDOIQAHITMMDAJ-UHFFFAOYSA-N 0.000 description 2
- 238000010197 meta-analysis Methods 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 235000020219 prebiotic milk Nutrition 0.000 description 2
- 230000000529 probiotic effect Effects 0.000 description 2
- 235000021391 short chain fatty acids Nutrition 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000007743 Acute Abdomen Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 206010002153 Anal fissure Diseases 0.000 description 1
- 208000016583 Anus disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003011 Appendicitis Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010006322 Breath holding Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000009531 Fissure in Ano Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 206010022773 Intracranial pressure increased Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000015815 Rectal disease Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000005189 cardiac health Effects 0.000 description 1
- 210000004534 cecum Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011841 epidemiological investigation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000002414 glycolytic effect Effects 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 201000009941 intracranial hypertension Diseases 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008897 memory decline Effects 0.000 description 1
- 201000003102 mental depression Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000008621 organismal health Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009323 psychological health Effects 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention relates to a composition with a bowel relaxing function, a preparation method and application thereof, and belongs to the field of functional foods. The invention provides a composition with a bowel relaxing function, which is prepared from the following raw materials in parts by weight: 1-3 parts of beta-1, 3/alpha-1, 3-glucan and 1-3 parts of stachyose. The invention also provides a preparation method and application of the composition. The invention combines beta-1, 3/alpha-1, 3-glucan and stachyose to play a remarkable synergistic effect, promote defecation and remarkably increase the water content of excrement.
Description
Technical Field
The invention relates to a composition with a bowel relaxing function, and belongs to the field of functional foods.
Background
The old people have poor intestinal peristalsis function because of less activities and even bed in the whole day; part of old people have too fine food due to missing teeth, so that intestinal peristalsis is weakened; in addition, elderly people often have vascular sclerosis, resulting in reduced gastrointestinal reflex. These factors can cause constipation to be a frequently occurring and common disorder in the elderly. Research shows that constipation not only can cause gastrointestinal dysfunction, but also can cause symptoms such as inappetence, abdominal pain, abdominal distention, nausea, vomiting and the like; "disharmony of stomach and night restlessness", gastrointestinal problems also affect normal rest of people; constipation is more detrimental to people suffering from hypertension and coronary heart disease, and especially when defecating, breath holding effort often results in angina, myocardial infarction and stroke, and even sudden death. In addition, long-term constipation is also an important cause of diseases such as acute abdomen, such as appendicitis and pancreatitis, anorectal diseases, such as hemorrhoids, cancers, such as colorectal cancer and breast cancer, senile dementia, and the like. Therefore, the elderly should pay particular attention to the prevention and treatment of constipation.
Constipation is mainly manifested by dry stool, difficult or incomplete after defecation, and obviously reduced times of completely emptying the stool without any cathartic medicine. Senile constipation refers to chronic constipation patients aged 60 years and older. Constipation is a common and frequently occurring disease of the elderly. Epidemiological investigation and retrospective study show that the prevalence of constipation for elderly people in China is 18.1%, which is significantly higher than 8.2% of the general population. Studies have demonstrated that constipation incidence increases with age. In China with middle-aged future, the aging situation is severe, the aging development is rapid, and the incidence rate of senile constipation is increased all the way.
Constipation seriously jeopardizes the physical and psychological health of the elderly, and various diseases can be induced or aggravated in the physical aspect, such as mental depression, anxiety and depression. Constipation, a common digestive system disease for the elderly, can cause gastrointestinal dysfunction, difficult defecation, dry stool, etc. to cause anal fissure, hemorrhoid, proctitis, intestinal obstruction, which in turn increases defecation difficulty, aggravates the retention of feces in colorectal, and forms malignant circulation. The feces stay in the intestinal tract for a long time, a large amount of harmful substances such as methane, phenol, ammonia and the like are generated under the action of bacteria, part of the harmful substances can diffuse to the central nervous system through the blood brain barrier due to small molecular weight, so that cerebral dysfunction such as memory decline, inattention, reaction retardation and the like is caused, senile dementia formation is accelerated, and the risk of intestinal cancer is increased due to the long-time stay of a large amount of harmful substances and cancerogenic substances. Difficult defecation, forced defecation can induce intracranial hypertension, angina pectoris, myocardial infarction, cerebral hemorrhage, apoplexy sudden death and other serious gravity cerebrovascular diseases and even cause death.
Currently, there is no safe and effective method for treating senile constipation, and oral laxatives are generally used as the main method. Long-term abuse of laxatives can lead to laxative dependence, colonic weakness, colonic blackness, diarrhea, and imbalance of water electrolyte balance and liver damage, and therefore, there is a need to develop a safe, effective, non-toxic method to solve the problem of constipation in the elderly.
At present, the prebiotics are used for improving constipation, related products and documents report that the prebiotics are isomaltooligosaccharides such as Xin Xiufeng and the like, and the isomaltooligosaccharides are reported to be a prebiotic substance with good physiological functions, have the effect of improving or preventing constipation, and can be widely applied to various foods, medicines and health care products. Wang Xiaolei et al, systematic evaluation and Meta analysis of the effect of probiotic/prebiotic formulations in treating functional constipation, journal of clinical drug treatment, 2014, disclose systematic evaluation and Meta analysis of the effect of probiotic/prebiotic formulations in treating functional constipation.
Gongmei and the like, and 2014 discloses that prebiotics have the effects of regulating intestinal flora to restore balance, relieving constipation and the like, and the results of the functional experiments of the prebiotic milk powder developed by animal feeding experiments show that: the prebiotic milk powder has obvious functions of lubricating the intestines and expelling toxin of rats. The prebiotics can proliferate beneficial bacteria in the intestinal tract, so as to regulate the balance of intestinal flora, and the pH value in the intestinal tract can be reduced by fermenting and degrading the beneficial bacteria into short-chain fatty acid, so that the intestinal acid environment can promote the peristalsis of the intestinal tract, the mucous secretion of the intestinal mucosa is increased, the excrement is immersed, and the excrement excretion is accelerated.
Most of the prebiotics commonly found on the market are dietary fibers and special carbohydrates, wherein the dietary fibers are: short chain fatty acid and gas can be generated after the dietary fiber is fermented by intestinal flora, the terminal contraction of ileum is stimulated, the movement of colon contraction is increased, the passing time of feces is shortened, and a small part of dietary fiber is fermented into the components of the feces. Special carbohydrates: such as polysaccharides, monosaccharides, oligosaccharides, etc. Helping the normal growth and balance maintenance of probiotics in the gastrointestinal parts. Increase the discharge of metabolism in the body and relieve constipation. Based on the action mechanism of the prebiotics, the effect on the water content of the excrement is small, and the single use effect is limited.
Beta-glucan is a natural dietary fiber that is found in natural plants and microorganisms such as grains, fungi, bacteria, and algae. Soluble beta-glucan has proven to have many health benefits, such as being able to slow the rate of food passage through the gut, thereby maintaining a longer feeling of satiety; slowing down the absorption of sugar in blood, helping to stabilize blood glucose levels; reducing the absorption of cholesterol in the digestive tract, maintaining healthy blood cholesterol levels, thereby promoting cardiac health; in addition, it has the functions of enhancing immune system, reducing inflammation, etc. Because of the special structure of the dextran, the physicochemical properties and the efficacy of different types of dextran are different.
Disclosure of Invention
The technical scheme of the invention is to provide a composition with a bowel relaxing function. The invention also provides a preparation method and application of the composition.
The invention provides a composition with a bowel relaxing function, which is prepared from the following raw materials in parts by weight:
1-3 parts of beta-1, 3/alpha-1, 3-glucan and 1-3 parts of stachyose.
Further preferably, the feed comprises the following raw materials in parts by weight:
1 part of beta-1, 3/alpha-1, 3-glucan and 1 part of stachyose.
The beta-1, 3/alpha-1, 3-glucan is a polysaccharide substance obtained by taking sucrose as a raw material, fermenting the sucrose by a bacterial strain zx09 and extracting the sucrose from a fermentation product. The method can be as follows: ZL201010146371.2, production license number: SC13151060400015.
Wherein, the preparation is prepared from beta-1, 3/alpha-1, 3-glucan and stachyose serving as active ingredients, and pharmaceutically or food acceptable auxiliary materials or auxiliary ingredients.
Wherein the preparation is tablet, capsule, pill, granule, or oral liquid.
The invention also provides a method for preparing the composition, which comprises the following steps:
a. weighing raw materials in weight proportion;
b. mixing, adding acceptable adjuvants or auxiliary components into food, and making into common preparation for functional food.
The invention also provides application of the composition in preparation of functional food for relieving constipation.
Further preferably, the functional food is a functional food having a function of shortening the time for constipation and defecation.
Further preferably, the functional food is a functional food having an increased fecal moisture content.
The invention also provides application of the composition in preparation of functional food or medicine with the function of relaxing bowels.
Stachyose is similar to other functional oligosaccharides, is not decomposed by human gastrointestinal digestive juice, can be utilized by beneficial bacteria such as bifidobacteria and lactobacillus in human intestinal tracts, and promotes the increment of the beneficial bacteria. The microecology theory holds that short-chain fatty acids such as acetic acid, lactic acid and the like generated by the bifidobacterium glycolytic oligosaccharide can promote intestinal peristalsis, so that the propulsion and movement capacity of intestinal tracts is enhanced, and the aim of preventing and treating constipation can be achieved. Both can improve constipation without a significant increase in fecal moisture content. And if one of them is used alone, the effect of improving constipation is not strong, and there is a possibility that the defect of long improvement time occurs. Stachyose has been reported in the literature to relieve constipation, but it is not possible to change the moisture content of feces.
Other glucans currently on the market, such as yeast beta-glucan, mushroom beta-glucan, oat beta-glucan, etc., share a common commonality: is insoluble or not fully soluble in water, and has a molecular structure with a side chain. In this case, the β -glucan cannot fully exert its own properties. To exert the effect of the beta-glucan itself, modification is needed, which greatly reduces the utilization rate of the beta-glucan. The beta-1, 3/alpha-1, 3-glucan is novel water-soluble glucan, extracellular polysaccharide obtained by fermenting an exclusive patent strain ZX09 has a linear structure formed by linking 7 beta-1, 3 glycosidic bonds and 2 alpha-1, 3 glycosidic bonds, and has no side chains. The beta-1, 3 glycosidic bond content exceeds 75%, and the biological activity is high. The raw materials are pure natural, have high solubility and can be well dissolved in water. Can resist acid and high temperature. Beta-1, 3/alpha-1, 3-glucan is one of the new food raw materials approved by China.
The beneficial effects of the invention are as follows:
1) The compound product of the invention has no auxiliary material;
2) Beta-1, 3/alpha-1, 3-glucan and stachyose are compounded, so that the health effect of different prebiotics in intestinal tracts is fully exerted while the effect of the beta-1, 3/alpha-1, 3-glucan and stachyose is exerted, the growth and the reproduction of beneficial intestinal bacteria are promoted in vivo, the microecological competitive advantage is formed, the microecological balance of the intestinal tracts is optimized, and the immunity is further improved, so that the health of organisms is maintained. Meanwhile, intestinal microecology can be improved, and bifidobacterium in the intestines ferment oligosaccharides to generate a large amount of short-chain fatty acids such as acetic acid, lactic acid and the like, so that the peristalsis of the intestinal tract can be promoted, the wettability of the excrement can be increased, and a certain osmotic pressure can be maintained, so that constipation can be improved and prevented. The beta-1, 3/alpha-1, 3-glucan compound stachyose formula has better bowel relaxing effect, can improve constipation symptoms, has no toxic or side effect, and has good application value and market prospect especially for senile constipation.
3) After the beta-1, 3/alpha-1, 3-glucan is compounded with stachyose, the defect that the water content of the excrement cannot be increased when stachyose is singly used is overcome.
4) Beta-glucan and water Su Tangfu the laxative effect of constipation mice is superior to yeast beta-glucan in beta-1, 3/alpha-1, 3-glucan.
According to the invention, beta-1, 3/alpha-1, 3-glucan and yeast beta-glucan are respectively combined with stachyose, and experimental results show that after the beta-1, 3/alpha-1, 3-glucan and stachyose are compounded, obvious synergistic effect is exerted, defecation is promoted, and the water content of excrement is obviously increased.
Description of the embodiments
EXAMPLE 1 preparation of the composition of the invention
Weighing the raw materials: beta-1, 3/alpha-1, 3-glucan 0.33g, stachyose 0.67g; mixing, sterilizing, and making into powder.
EXAMPLE 2 preparation of the composition of the invention
Weighing the raw materials: mixing beta-1, 3/alpha-1, 3-glucan 0.5g and stachyose 0.5g, adding starch, granulating, grading, and making into capsule.
EXAMPLE 3 preparation of the composition of the invention
Weighing the raw materials: beta-1, 3/alpha-1, 3-glucan 0.67g, stachyose 0.33g; mixing, adding starch, granulating with water, and granulating to obtain granule.
The following generally specific efficacy tests demonstrate the beneficial effects of the present invention.
Test examples efficacy test of the compositions of the invention
Beta-1, 3/alpha-1, 3-glucan and yeast beta-glucan are respectively combined with stachyose, so that the synergistic effect of relaxing bowels and the influence on the water content of excrement after the combination of the beta-1, 3/alpha-1, 3-glucan and the yeast beta-glucan are seen.
1. Animals
100 healthy male Kunming mice were kept in a barrier-grade environment at 25℃and 60% relative humidity.
2. Material
Stachyose, yeast beta-glucan, beta-1, 3/alpha-1, 3-glucan; loperamide hydrochloride; gum arabic; activated carbon powder.
3. Experimental method
3.1 preparation of ink
Accurately weighing 50g of gum arabic, adding 400mL of distilled water, boiling and dissolving to transparency, adding 25g of active carbon powder, boiling with slow fire for 3 times, naturally cooling the solution, then fixing the volume to 500mL with distilled water, placing into a refrigerator for 4 ℃ preservation, and shaking uniformly before use.
3.2 mice defecation experiment
3.2.1 grouping of animals and model building
After 100 mice were adaptively fed for 7d in the experimental environment, they were randomly divided into 10 groups of 10 mice each. The experiments were divided into a negative control group (10), a model group (10) and an experiment group (80). The negative control group and the model group are used for feeding water, the experimental group is used for continuously feeding water according to the concentration of 125 mg/kg.bw, different samples are fed, and after 14 days of continuous feeding, each group of mice is fasted without water forbidding for 20 hours. Both the model group and the experimental group were stomach-irrigated with loperamide 10 mg/kg.bw to establish a constipation model, and the negative control group was distilled water.
The experimental groups were:
1) Beta-1, 3/alpha-1, 3-glucan group
2) Stachyose group
3) Beta-1, 3/alpha-1, 3-glucan + stachyose (1: 3) Group of
4) Beta-1, 3/alpha-1, 3-glucan + stachyose (1: 2) Group of
5) Beta-1, 3/alpha-1, 3-glucan + stachyose (1: 1) Group of
6) Beta-1, 3/alpha-1, 3-glucan + stachyose (2: 1) Group of
7) Yeast β -glucan + stachyose (1: 1) Group of
8) Yeast β -glucan + stachyose (2: 1) Group of
3.2.2 observations of Experimental indicators
After 0.5 hour of loperamide administration, each group of mice was ink filled and timing was started.
Mice that had completed the gavage were placed in separate cages, given sufficient water and fed normally. Starting from the ink filling, the first black stool discharge time of each mouse was recorded, the black stools discharged from each mouse within 6 hours were collected, and the total weight of the black stools was counted.
After the experiment is finished, the collected black stool sample of each mouse is placed in an electrothermal blowing drying oven and dried to constant weight at 105 ℃. The fecal moisture content was calculated as follows:
fecal moisture content (%) = [ fecal wet weight (g) -fecal dry weight (g) ]/fecal wet weight (g) ×100
4. Results
TABLE 1 influence of different samples on the time to discharge of first black stool from constipation mice
Note that: in comparison with the negative control group, ∆∆ p is less than 0.01; in contrast to the set of models, * P＜0.05， ** p is less than 0.01; compared with the beta-1, 3/alpha-1, 3-glucan and stachyose (1:1) group, # P＜0.05， ## P＜0.01。
(1) compared with a negative control group, the initial black stool discharge time of the mice in the model group is extremely obviously different (P is less than 0.01), which indicates that the model modeling of the constipation model of the mice induced by loperamide hydrochloride is successful.
(2) Compared with the model group, the first granule black stool discharge time of the beta-1, 3/alpha-1, 3-glucan group, stachyose group, beta-1, 3/alpha-1, 3-glucan compound stachyose (1:3) group and yeast beta-glucan compound stachyose (1:2) group is improved, but no obvious difference exists.
(3) Compared with a model group, beta-1, 3/alpha-1, 3-glucan and stachyose are compounded 1: 2. 1: 1. 2: the first granule of constipation mice in group 1 have a significant difference in the discharge time of black stool (P < 0.05), wherein beta-1, 3/alpha-1, 3-glucan is compounded with stachyose 1: group 1 had very significant differences (P < 0.01).
(4) Compared with the beta-1, 3/alpha-1, 3-glucan compound stachyose (1:1) group, the first granule black stool discharge time of other experimental sample groups is significantly different (P < 0.05).
(5) The effect of beta-1, 3/alpha-1, 3-glucan compounded stachyose (1:1) group on shortening the first granule black stool discharge time of the constipation mice is optimal.
TABLE 2 Effect of different samples on Constipation mouse faeces moisture content
Note that: in comparison with the negative control group, ∆ P＜0.05， ∆∆ p is less than 0.01; in contrast to the set of models, * P＜0.05， ** p is less than 0.01; compared with the beta-1, 3/alpha-1, 3-glucan and stachyose (1:1) group, # P＜0.05， ## P＜0.01。
(1) compared with a negative control group, the water content of the feces of the mice in the model group is extremely obviously different (P is less than 0.01), which indicates that the model modeling of the constipation model of the mice induced by loperamide hydrochloride is successful.
(2) Compared with the model group, the fecal water content of the beta-1, 3/alpha-1, 3-glucan group, stachyose group, beta-1, 3/alpha-1, 3-glucan compound stachyose (1:3) group and yeast beta-glucan compound stachyose (1:2) group is improved, but no obvious difference exists.
(3) Compared with a model group, beta-1, 3/alpha-1, 3-glucan and stachyose are compounded 1: 2. 1: 1. 2: the water content of the constipation mice in group 1 has very significant difference (P < 0.01).
(4) The fecal moisture content of the other experimental sample groups was significantly different (P < 0.05) compared to the beta-1, 3/alpha-1, 3-glucan complex stachyose (1:1) group.
(5) The water content of the mouse feces of the negative control group also showed a very significant difference (P < 0.01) compared to the beta-1, 3/alpha-1, 3-glucan complex stachyose (1:1) group.
(6) The effect of compounding stachyose (1:1) with beta-1, 3/alpha-1, 3-glucan on increasing the water content of the feces is optimal.
In conclusion, the method comprises the steps of,
(1) the beta-1, 3/alpha-1, 3-glucan and the water Su Tangfu are compounded to produce a synergistic effect, so that intestinal peristalsis of a constipation mouse is promoted, defecation is promoted, wherein the following components are compounded in proportion 1:1, the synergy is optimal;
(2) the beta-1, 3/alpha-1, 3-glucan and stachyose can be compounded to increase the water content of the excrement;
(3) the effect of relaxing the bowels by compounding beta-1, 3/alpha-1, 3-glucan and stachyose is better than that of compounding yeast beta-glucan and stachyose.
5. Conclusion(s)
(1) Beta-1, 3/alpha-1, 3-glucan and water Su Tangfu are compounded to perform a synergistic effect, so that the defecation time of a constipation mouse can be obviously shortened, the water content of the excrement is obviously increased, and constipation is relieved. And effectively improves the water content of the feces of the mice with constipation when using stachyose.
(2) Beta-glucan and water Su Tangfu the laxative effect of constipation mice is superior to yeast beta-glucan in beta-1, 3/alpha-1, 3-glucan.
The composition can obviously increase the water content of the excrement, and the water content of the excrement is related to whether the excrement is smooth or not. When the digesta enters the large intestine (cecum) from the small intestine, the water content is generally over 90%, the digesta gradually decreases during passage through the large intestine, the water content is approximately 75% after reaching the rectum to form stool, the liquid stool with diarrhea is approximately 90%, the soft stool is approximately 77%, the normal stool is approximately 75%, and the dry and hard stool is less than 72%. From 72% moisture to 90% moisture, only 18% but 240-fold difference in viscosity, from thin to hard feces.
Too much water in the feces causes that the feces are not formed, the feces are thin and soft, even become watery, and diarrhea is easy to cause; or too little water content, causing too dry feces, being spherical-like, harder and easy to cause constipation. The water content of the feces is related to the stimulation of the intestinal tract. Mechanical stimulation can increase damage to the mucosa and disrupt the mucosal barrier. Chronic inflammatory reactions, such as local tissue redness, pain, ulceration, etc., are caused by long-term mechanical stimulation of the intestinal tract. But also long-term mechanical stimulation may lead to structural changes in the intestinal wall, such as thickening, fibrosis, etc. The non-mechanical stimulation can shorten the time for the content (feces) to pass through the intestinal tract, reduce the pressure of the colon, reduce the contact time between the harmful substances in the intestine and the intestinal wall, promote the intestinal peristalsis and promote the defecation.
The raw material beta-1, 3/alpha-1, 3-glucan of the invention relieves constipation by non-mechanical stimulation of intestinal tracts, increases the moisture and volume of excrement, can absorb a large amount of moisture to expand as a fully water-soluble high-viscosity dietary fiber, increases the volume of the excrement, and softens the excrement to ensure that the excrement is easier to discharge.
Finally, it should be noted that: the above embodiments are only for illustrating the technical solution of the present invention, and not for limiting the same; although the invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical scheme described in the foregoing embodiments can be modified or some or all of the technical features thereof can be replaced by equivalents; such modifications and substitutions do not depart from the spirit of the invention.
Claims (8)
1. A composition with bowel relaxing function, characterized in that: the composite material consists of the following raw materials in parts by weight:
1 part of beta-1, 3/alpha-1, 3-glucan and 2 parts of stachyose; or (b)
1 part of beta-1, 3/alpha-1, 3-glucan and 1 part of stachyose; or (b)
2 parts of beta-1, 3/alpha-1, 3-glucan and 1 part of stachyose;
the beta-1, 3/alpha-1, 3-glucan is a polysaccharide substance obtained by taking sucrose as a raw material, fermenting the sucrose by a bacterial strain zx09 and extracting the sucrose from a fermentation product.
2. A composition with bowel relaxing function, characterized in that: the preparation is a common preparation in food prepared by taking beta-1, 3/alpha-1, 3-glucan and stachyose as active ingredients and adding acceptable auxiliary materials or auxiliary ingredients in the food;
the weight ratio of the beta-1, 3/alpha-1, 3-glucan and stachyose is as follows:
1 part of beta-1, 3/alpha-1, 3-glucan and 2 parts of stachyose; or (b)
1 part of beta-1, 3/alpha-1, 3-glucan and 1 part of stachyose; or (b)
2 parts of beta-1, 3/alpha-1, 3-glucan and 1 part of stachyose;
the beta-1, 3/alpha-1, 3-glucan is a polysaccharide substance obtained by taking sucrose as a raw material, fermenting the sucrose by a bacterial strain zx09 and extracting the sucrose from a fermentation product.
3. The composition of claim 2, wherein: the preparation is tablets, capsules, pills, granules and oral liquid.
4. A process for preparing the composition of any one of claims 2 or 3, characterized by: it comprises the following steps:
a. weighing raw materials in weight proportion;
b. mixing, adding acceptable adjuvants or auxiliary components into food, and making into pharmaceutically or food common preparation.
5. Use of a composition according to any one of claims 1-3 for the preparation of a functional food for improving or alleviating constipation.
6. Use according to claim 5, characterized in that: the functional food is a functional food capable of shortening constipation and defecation time.
7. Use according to claim 5, characterized in that: the functional food is a functional food with the function of increasing the water content of the excrement.
8. Use of a composition according to any one of claims 1-3 for the preparation of a medicament having laxative properties.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311149911.6A CN116869169B (en) | 2023-09-07 | 2023-09-07 | Composition with function of relaxing bowels and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311149911.6A CN116869169B (en) | 2023-09-07 | 2023-09-07 | Composition with function of relaxing bowels and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116869169A CN116869169A (en) | 2023-10-13 |
| CN116869169B true CN116869169B (en) | 2023-11-28 |
Family
ID=88259151
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311149911.6A Active CN116869169B (en) | 2023-09-07 | 2023-09-07 | Composition with function of relaxing bowels and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116869169B (en) |
Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6363366A (en) * | 1986-09-03 | 1988-03-19 | Iwatani & Co | Healthy food for promoting control of intestinal function |
| CN101935623A (en) * | 2010-04-14 | 2011-01-05 | 南京理工大学 | Agrobacterium ZX09, water-soluble beta-glucan prepared from Agrobacterium ZX09 and preparation method thereof and application on reducing blood sugar |
| CN102357105A (en) * | 2011-09-30 | 2012-02-22 | 云南道衍生物科技有限公司 | Combination with effect of enhancing immunity and application thereof |
| CN106265889A (en) * | 2016-08-30 | 2017-01-04 | 山东格林康宝药业有限公司 | A kind of diet therapy formula of anti-curing cancers |
| CN107212378A (en) * | 2016-03-22 | 2017-09-29 | 内蒙古伊利实业集团股份有限公司 | A kind of function composition with regulation enteron aisle and its application |
| CN107242579A (en) * | 2016-11-09 | 2017-10-13 | 易军如 | A kind of complex prebiotics and its application |
| KR101941058B1 (en) * | 2017-08-30 | 2019-01-23 | 지우안 티안 | Antaccharide materials and preparation method of antaccharide materials that can eliminate 92% of free radicals |
| CN110237092A (en) * | 2019-06-11 | 2019-09-17 | 厦门蓝特生物科技有限公司 | A kind of composition for treating constipation |
| CN111778300A (en) * | 2020-07-31 | 2020-10-16 | 四川合泰新光生物科技有限公司 | Beta-1, 3-glucan and preparation method and application thereof |
| JP2020178684A (en) * | 2019-04-23 | 2020-11-05 | 学校法人慶應義塾 | Composition for improving intestinal flora diversity |
| JP2020178685A (en) * | 2019-04-23 | 2020-11-05 | 学校法人慶應義塾 | Composition for preventing, treating or suppressing intestinal disorders |
| CN113331335A (en) * | 2021-05-28 | 2021-09-03 | 湖北明德医疗科技有限责任公司 | Prebiotic composition, solid beverage and preparation method of solid beverage |
| CN116549494A (en) * | 2023-07-07 | 2023-08-08 | 四川合泰新光生物科技有限公司 | Beta-1, 3/alpha-1, 3-glucan compound composition with bowel relaxing function and preparation method and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10973245B2 (en) * | 2016-06-24 | 2021-04-13 | Yessinergy Holding S/A | Immunomodulatory and growth promoting and controlling composition of intestinal microbiota undesirable bacteria and its use |
-
2023
- 2023-09-07 CN CN202311149911.6A patent/CN116869169B/en active Active
Patent Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6363366A (en) * | 1986-09-03 | 1988-03-19 | Iwatani & Co | Healthy food for promoting control of intestinal function |
| CN101935623A (en) * | 2010-04-14 | 2011-01-05 | 南京理工大学 | Agrobacterium ZX09, water-soluble beta-glucan prepared from Agrobacterium ZX09 and preparation method thereof and application on reducing blood sugar |
| CN102357105A (en) * | 2011-09-30 | 2012-02-22 | 云南道衍生物科技有限公司 | Combination with effect of enhancing immunity and application thereof |
| CN107212378A (en) * | 2016-03-22 | 2017-09-29 | 内蒙古伊利实业集团股份有限公司 | A kind of function composition with regulation enteron aisle and its application |
| CN106265889A (en) * | 2016-08-30 | 2017-01-04 | 山东格林康宝药业有限公司 | A kind of diet therapy formula of anti-curing cancers |
| CN107242579A (en) * | 2016-11-09 | 2017-10-13 | 易军如 | A kind of complex prebiotics and its application |
| KR101941058B1 (en) * | 2017-08-30 | 2019-01-23 | 지우안 티안 | Antaccharide materials and preparation method of antaccharide materials that can eliminate 92% of free radicals |
| JP2020178684A (en) * | 2019-04-23 | 2020-11-05 | 学校法人慶應義塾 | Composition for improving intestinal flora diversity |
| JP2020178685A (en) * | 2019-04-23 | 2020-11-05 | 学校法人慶應義塾 | Composition for preventing, treating or suppressing intestinal disorders |
| CN110237092A (en) * | 2019-06-11 | 2019-09-17 | 厦门蓝特生物科技有限公司 | A kind of composition for treating constipation |
| CN111778300A (en) * | 2020-07-31 | 2020-10-16 | 四川合泰新光生物科技有限公司 | Beta-1, 3-glucan and preparation method and application thereof |
| CN113331335A (en) * | 2021-05-28 | 2021-09-03 | 湖北明德医疗科技有限责任公司 | Prebiotic composition, solid beverage and preparation method of solid beverage |
| CN116549494A (en) * | 2023-07-07 | 2023-08-08 | 四川合泰新光生物科技有限公司 | Beta-1, 3/alpha-1, 3-glucan compound composition with bowel relaxing function and preparation method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 水苏糖生产、功能及其应用简述;黄伟志等;食品工业科技;第39卷(第01期);第328页右栏第3.2节 * |
| 水苏糖的制备、功能及应用;徐宝财;张桂菊;;北京工商大学学报(自然科学版);第29期(第01期);第1-5页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116869169A (en) | 2023-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5270058B2 (en) | Inulin products with improved nutrition | |
| JP4626752B2 (en) | Novel uses of carbohydrates and compositions | |
| CN112370470B (en) | Microecological preparation for reconstructing intestinal microecology | |
| JP2012111771A (en) | Dietary fiber formulation, and method of administration | |
| CN112544920A (en) | Composition for improving constipation and preparation method thereof | |
| JP5992654B2 (en) | Composition for intestinal regulation and / or improvement of bowel movement | |
| CN103393713A (en) | Hyaluronic acid and application of salt thereof in preparing medicines for treating constipation | |
| CN1177593C (en) | Fructan containing compsn. for prevention and treatment of colon cancer | |
| CN101433332B (en) | Food replenisher for improving function of intestinal canal, moistening intestines and relaxing the bowels, and preparation method thereof | |
| CN116549494B (en) | Beta-1, 3/alpha-1, 3-glucan compound composition with bowel relaxing function and preparation method and application thereof | |
| JPH05255097A (en) | Liquid composition | |
| TW200930385A (en) | Composition with active ingredient combination for the treatment of constipation | |
| CN116869169B (en) | Composition with function of relaxing bowels and preparation method and application thereof | |
| CN116584597A (en) | Western Mei Yinpin formula for improving intestinal functions and preparation method thereof | |
| JP4113242B1 (en) | Gastrointestinal symptoms | |
| Godding | Laxatives and the special role of senna | |
| CN102058616B (en) | Application of soracan gum used as medicine for preventing and treating astriction | |
| JP2005179316A (en) | Composition with constipation ameliorating action | |
| Oku et al. | Suppressive effect of cellulose on osmotic diarrhea caused by maltitol in healthy female subjects | |
| CN116268414A (en) | Composition for improving gastrointestinal function and preventing constipation and application thereof | |
| JP4071818B1 (en) | sweetener | |
| CN115297878A (en) | Compositions for enhancing urolithin production in human subjects | |
| CN112401242B (en) | Microecological preparation for reconstructing intestinal microecology and application thereof | |
| Widjanarko et al. | Laxative potential of the konjac flour (Amorphophallus muelleri Blume) in treatment of loperamide induced constipation on Sprague Dawley rats | |
| EP3697383B1 (en) | Composition for treating constipation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |